Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
NCT00328120
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Breast Cancer
Interventions
DRUG:
Fulvestrant
Sponsor
AstraZeneca